Li-yu Zhou

发表

Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes

Saijuan Chen, Lanping Xu, Xiao Li, 2016, Tumor Biology.

Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes

Xiao Li, Chun-kang Chang, Feng Xu, 2017, Scientific Reports.

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Ling Wu, Yang Zhu, Xiao Li, 2014, Scientific Reports.

Establishment and Validation of an Updated Diagnostic FCM Scoring System Based on Pooled Immunophenotyping in CD34+ Blasts and Its Clinical Significance for Myelodysplastic Syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2014, PloS one.

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Juan Guo, 2021, Clinical Epigenetics.

Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.

Xiao Li, Chun-kang Chang, Juan Guo, 2017, American journal of translational research.

Distinct Clinical and Experimental Characteristics in the Patients Younger than 60 Years Old with Myelodysplastic Syndromes

Z. Xiao, Xiao Li, Chun-kang Chang, 2013, PloS one.

Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2015, Nature Communications.

[Yield of CD34(+) cells in graft can be increased significantly by G-CSF used at appropriate time after chemotherapy for AutoPBSCT].

Hong Liu, Xiao Li, Chun-kang Chang, 2011, Zhongguo shi yan xue ye xue za zhi.

Interleukin-17-producing CD4+ T lymphocytes are increased in patients with primary immune thrombocytopenia

Xiao Li, Chun-kang Chang, Y. Tao, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.

Xiao Li, Chun-kang Chang, Lingyun Wu, 2013, Leukemia research.

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine

Xiao Li, Chun-kang Chang, Y. Tao, 2019, Journal of Cancer Research and Clinical Oncology.

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis

Q. Song, M. Hou, Xiao Li, 2014, PloS one.

Cytogenetic Response Based On Revised IPSS Cytogenetic Risk Stratification and Minimal Residual Disease Monitoringby FISH In MDS Patients Treated By Low-Dose Decitabine

Chun-kang Chang, Lingyun Wu, Dong-dong Wu, 2013 .

High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Wenhui Shi, 2016, Journal of Translational Medicine.

Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome

Xiao Li, Chun-kang Chang, Juan Guo, 2017, Leukemia & lymphoma.

[Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].

Xiao Li, Chun-kang Chang, Lingyun Wu, 2009, Zhongguo shi yan xue ye xue za zhi.

High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome

Qi He, Feng Xu, Lingyun Wu, 2016, Journal of Translational Medicine.

Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study

Xiao Li, Chun-kang Chang, Lingyun Wu, 2016, Leukemia & lymphoma.

Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes

Yang Zhu, Xiao Li, Chun-kang Chang, 2015, Nature Communications.

ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS.

Cheng-Long Hu, Juan Guo, Lingyun Wu, 2023, Science Advances.

NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy

Xiao Li, Chun-kang Chang, Juan Guo, 2020, British Journal of Haematology.